Literature DB >> 15463741

Mechanisms of drug resistance in Leishmania.

M Ouellette1, B Papadopoulou.   

Abstract

The emergence of drug resistance in protozoan parasites is a major obstacle to their control. Since vaccines are not yet in sight for several of these parasites, there is on urgent need to develop new and better drugs. These antimicrobial agents will possibly be more expensive, and will therefore impose on additional burden in health-care costs and in the planning of public health policies of the developing countries. A better understanding of drug resistance, to try to circumvent or overcome it, and the search for new specific cellular targets of parasites are warranted. The development, in vitro, of drug-resistant parasite cell lines has been instrumental in our understanding of the mechanisms of drug resistance in parasitic protozoans. Marc Ouellette and Barbara Popodopoulou here present on overview of the recent progress on the elucidation of mechanisms of drug resistance in the protozoan parasite Leishmania, selected under laboratory conditions.

Entities:  

Year:  1993        PMID: 15463741     DOI: 10.1016/0169-4758(93)90135-3

Source DB:  PubMed          Journal:  Parasitol Today        ISSN: 0169-4758


  39 in total

1.  Expression of green fluorescent protein as a marker for effects of antileishmanial compounds in vitro.

Authors:  S W Kamau; F Grimm; A B Hehl
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  Effect of large targeted deletions on the mitotic stability of an extra chromosome mediating drug resistance in Leishmania.

Authors:  P Dubessay; C Ravel; P Bastien; M F Lignon; B Ullman; M Pagès; C Blaineau
Journal:  Nucleic Acids Res       Date:  2001-08-01       Impact factor: 16.971

3.  Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages.

Authors:  C Dumas; M Ouellette; J Tovar; M L Cunningham; A H Fairlamb; S Tamar; M Olivier; B Papadopoulou
Journal:  EMBO J       Date:  1997-05-15       Impact factor: 11.598

4.  Characterization of sinefungin-resistant Leishmania donovani promastigotes.

Authors:  M A Phelouzat; F Lawrence; M Robert-Gero
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

5.  3'-Deoxy-3'-fluoroinosine as a potent antileishmanial agent. The metabolism and selective cytotoxic effect of 3'-deoxy-3'-fluoroinosine against Leishmania tropica and L. donovani in vitro and in vivo.

Authors:  I S Shin; H Tanifuji; Y Arata; Y Morizawa; T Nakayama; Y Wataya
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

6.  Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport.

Authors:  M Müller; C Meijer; G J Zaman; P Borst; R J Scheper; N H Mulder; E G de Vries; P L Jansen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

7.  Induced resistance to methionyl-tRNA synthetase inhibitors in Trypanosoma brucei is due to overexpression of the target.

Authors:  Ranae M Ranade; J Robert Gillespie; Sayaka Shibata; Christophe L M J Verlinde; Erkang Fan; Wim G J Hol; Frederick S Buckner
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

8.  Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania.

Authors:  M Chen; S B Christensen; J Blom; E Lemmich; L Nadelmann; K Fich; T G Theander; A Kharazmi
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

9.  Frequency of drug resistance gene amplification in clinical leishmania strains.

Authors:  C Mary; F Faraut; M Deniau; J Dereure; K Aoun; S Ranque; R Piarroux
Journal:  Int J Microbiol       Date:  2010-07-12

10.  Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: a template for drug design.

Authors:  Ahilan Saravanamuthu; Tim J Vickers; Charles S Bond; Mark R Peterson; William N Hunter; Alan H Fairlamb
Journal:  J Biol Chem       Date:  2004-04-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.